eTS database_Shirotake et al_Molecular and Clinical Oncology 2018

The renal tumors or metastatic lesions of 127 were evaluated by CT or MRI 90 days before molecular targeted tharapy (MTT) treatment (as baseline scans) as well as between 30 and 90 days after MTT (as first post baseline scans). Two urologists (HK and TO) and a radiologist (SM) blindly measured the sum of the longest diameters (SLD) in each case, based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumor shrinkage was determined based on the change in SLD of target lesions at the first post baseline scan.